
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 3, 2021

Mallinckrodt plc

(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction
of incorporation)

001-35803
(Commission
File Number)

98-1088325
(IRS Employer
Identification No.)

**College Business & Technology Park, Cruiserath,
Blanchardstown, Dublin 15, Ireland**
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **+353 1 696 0000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 3, 2021, Mallinckrodt plc (the "Company" or "Mallinckrodt") provided its financial results for the three months ended June 25, 2021 in the attached Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 25, 2021.

The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as otherwise expressly set forth by specific reference in such a filing.

NON-GAAP FINANCIAL MEASURES

Exhibit 99.1 contains financial measures, including adjusted EBITDA and net sales growth on a constant-currency basis, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations.

Adjusted EBITDA represents amounts prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and adjusts for certain items that management believes are not reflective of the operational performance of the business. Consolidated adjusted EBITDA represents net loss, adjusted for interest expense, net, taxes, depreciation and amortization and certain items that management believes are not reflective of the operational performance of the business and additional adjustments. These adjustments include, but are not limited to, restructuring charges, net; non-restructuring impairment charges; discontinued operations; changes in fair value of contingent consideration obligations; significant legal and environmental charges; divestitures; separation costs; unrealized gain on equity investment; reorganization items, net; share-based compensation and other items identified by the Company.

Segment net sales growth on a constant-currency basis measures the change in segment net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.

The Company has provided these adjusted financial measures because they are used by management, along with financial measures in accordance with GAAP, to evaluate the company's operating performance. In addition, the Company believes that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these adjusted measures provides useful information about the Company's performance across reporting periods on a consistent basis by excluding items that the Company does not believe are indicative of its core operating performance. Reconciliations of these financial measures to the most directly comparable GAAP financial measures are included in Exhibit 99.1.

These adjusted measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Exhibit</u>
99.1	Second Quarter Financial Results.
104	Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MALLINCKRODT PLC
(registrant)

Date: August 3, 2021

By: /s/ Bryan M. Reasons

Bryan M. Reasons
Executive Vice President and Chief Financial Officer
(principal financial officer)

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)

	Three Months Ended			
	June 25, 2021	Percent of Net sales	June 26, 2020	Percent of Net sales
Net sales (includes retrospective one-time charge of \$534.4 million related to the Medicaid lawsuit for the three months ended June 26, 2020)	\$ 546.4	100.0 %	\$ 166.5	100.0 %
Cost of sales	331.6	60.7	386.7	232.3
Gross profit (loss)	214.8	39.3	(220.2)	(132.3)
Selling, general and administrative expenses	145.0	26.5	231.3	138.9
Research and development expenses	52.8	9.7	82.9	49.8
Restructuring charges, net	6.1	1.1	14.4	8.6
Non-restructuring impairment charges	—	—	63.5	38.1
Gains on divestiture	—	—	(0.6)	(0.4)
Opioid-related litigation settlement loss	—	—	8.5	5.1
Medicaid lawsuit	—	—	105.3	63.2
Operating income (loss)	10.9	2.0	(725.5)	(435.7)
Interest expense	(52.4)	(9.6)	(64.2)	(38.6)
Interest income	—	—	1.0	0.6
Other income (expense), net	11.3	2.1	(0.6)	(0.4)
Reorganization items, net	(109.5)	(20.0)	—	—
Loss from continuing operations before income taxes	(139.7)	(25.6)	(789.3)	(474.1)
Income tax (benefit) expense	(33.5)	(6.1)	161.3	96.9
Loss from continuing operations	(106.2)	(19.4)	(950.6)	(570.9)
Income from discontinued operations, net of income taxes	0.4	0.1	17.5	10.5
Net loss	\$ (105.8)	(19.4)%	\$ (933.1)	(560.4)%
Basic loss per share:				
Loss from continuing operations	\$ (1.25)		\$ (11.25)	
Income from discontinued operations	—		0.21	
Net loss	\$ (1.25)		\$ (11.04)	
Diluted loss per share:				
Loss from continuing operations	\$ (1.25)		\$ (11.25)	
Income from discontinued operations	—		0.21	
Net loss	\$ (1.25)		\$ (11.04)	
Weighted-average number of shares outstanding				
Basic weighted-average shares outstanding	84.7		84.5	
Diluted weighted-average shares outstanding	84.7		84.5	

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)

	Three Months Ended							
	June 25, 2021				June 26, 2020			
	Gross Profit	SG&A	R&D	Adjusted EBITDA	Gross Profit	SG&A	R&D	Adjusted EBITDA
Net loss	\$ 214.8	\$ 145.0	\$ 52.8	\$ (105.8)	\$ (220.2)	\$ 231.3	\$ 82.9	\$ (933.1)
Adjustments:								
Interest expense, net	—	—	—	52.4	—	—	—	63.2
Income taxes	—	—	—	(33.5)	—	—	—	161.3
Depreciation ⁽¹⁾	17.0	(4.3)	(1.5)	22.8	17.5	(5.5)	(1.7)	24.7
Amortization	144.4	(0.8)	—	145.2	190.8	(0.8)	—	191.6
Restructuring charges, net	—	—	—	6.1	—	—	—	14.4
Non-restructuring impairment charge	—	—	—	—	—	—	—	63.5
Income from discontinued operations	—	—	—	(0.4)	—	—	—	(17.5)
Change in contingent consideration fair value	—	(5.3)	—	5.3	—	4.9	—	(4.9)
Significant legal and environmental charges	—	—	—	—	534.4	(17.2)	—	665.4
Gains on divestiture	—	—	—	—	—	—	—	(0.6)
Separation costs	—	(0.3)	—	0.3	—	(20.7)	—	20.7
Unrealized (gain) loss on equity investment	—	—	—	(4.8)	—	—	—	2.4
R&D upfront payment	—	—	—	—	—	—	(5.0)	5.0
Reorganization items, net	—	—	—	109.5	—	—	—	—
Share-based compensation	0.1	(1.9)	(0.4)	2.4	0.3	(5.2)	(1.1)	6.6
As adjusted:	<u>\$ 376.3</u>	<u>\$ 132.4</u>	<u>\$ 50.9</u>	<u>\$ 199.5</u>	<u>\$ 522.8</u>	<u>\$ 186.8</u>	<u>\$ 75.1</u>	<u>\$ 262.7</u>

⁽¹⁾ Includes \$0.6 million of accelerated depreciation in selling general and administrative ("SG&A") related to restructuring charges incurred during the three months ended June 25, 2021.

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT OPERATING INCOME ⁽¹⁾
(unaudited, in millions)

	Three Months Ended	
	June 25, 2021	June 26, 2020
Specialty Brands	\$ 186.6	252.7
Specialty Generics	26.9	49.2
Segment operating income	213.5	301.9
Allocated amounts:		
Corporate and unallocated expenses ⁽²⁾	(25.7)	(52.7)
Depreciation and amortization	(168.1)	(216.3)
Share-based compensation	(2.4)	(6.6)
Restructuring charges, net	(6.1)	(14.4)
Non-restructuring impairment charge	—	(63.5)
Preparation costs	(0.3)	(20.7)
R&D upfront payment	—	(5.0)
Opioid-related litigation settlement loss	—	(8.5)
Medicaid lawsuit	—	(639.7)
Operating income (loss)	\$ 10.9	(725.5)

⁽¹⁾ During the three months ended September 25, 2020, the Company began excluding depreciation and share-based compensation from its evaluation of the operating results of its segments. As a result, prior period segment operating income has been recast to reflect this change on a comparable basis.

⁽²⁾ Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)

	Three Months Ended		Percent change	Currency impact	Constant-currency growth
	June 25, 2021	June 26, 2020			
Specialty Brands	\$ 381.5	\$ 522.8	(27.0)%	0.4 %	(27.4)%
Specialty Generics	164.9	178.1	(7.4)	0.2	(7.6)
Segment net sales	546.4	700.9	(22.0)	0.3	(22.3)
Medicaid lawsuit	—	(534.4)	*	*	*
Net sales	<u>\$ 546.4</u>	<u>\$ 166.5</u>	228.2 %	0.3 %	227.9 %

*Not meaningful

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)

	Three Months Ended		Percent change	Currency impact	Constant-currency growth
	June 25, 2021	June 26, 2020			
Specialty Brands					
Acthar Gel	\$ 151.5	\$ 213.7	(29.1)%	— %	(29.1)%
INOmax	105.9	154.9	(31.6)	0.2	(31.8)
Ofirmev	6.5	52.4	(87.6)	—	(87.6)
Therakos	68.5	47.8	43.3	3.5	39.8
Amitiza	44.8	49.4	(9.3)	—	(9.3)
Other	4.3	4.6	(6.5)	—	(6.5)
Specialty Brands Total	381.5	522.8	(27.0)	0.4	(27.4)
Specialty Generics					
Hydrocodone (API) and hydrocodone-containing tablets	20.5	25.4	(19.3)	—	(19.3)
Oxycodone (API) and oxycodone-containing tablets	17.1	15.0	14.0	—	14.0
Acetaminophen (API)	51.7	55.5	(6.8)	—	(6.8)
Other controlled substances	69.0	77.8	(11.3)	0.5	(11.8)
Other	6.6	4.4	50.0	—	50.0
Specialty Generics Total	164.9	178.1	(7.4)	0.2	(7.6)
Segment net sales	546.4	700.9	(22.0)	0.3	(22.3)
Medicaid lawsuit	—	(534.4)	*	*	*
Net sales	<u>\$ 546.4</u>	<u>\$ 166.5</u>	228.2 %	0.3 %	227.9 %

*Not meaningful

MALLINCKRODT PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)

	Six Months Ended			
	June 25, 2021	Percent of Net sales	June 26, 2020	Percent of Net sales
Net sales (includes retrospective one-time charge of \$534.4 million related to the Medicaid lawsuit for the six months ended June 26, 2020)	\$ 1,104.4	100.0 %	\$ 832.3	100.0 %
Cost of sales	639.2	57.9	768.7	92.4
Gross profit	465.2	42.1	63.6	7.6
Selling, general and administrative expenses	281.0	25.4	462.4	55.6
Research and development expenses	119.0	10.8	160.3	19.3
Restructuring charges, net	6.5	0.6	12.6	1.5
Non-restructuring impairment charges	64.5	5.8	63.5	7.6
Losses (gains) on divestiture	0.8	0.1	(0.4)	—
Opioid-related litigation settlement gain	—	—	(8.3)	(1.0)
Medicaid lawsuit	—	—	105.3	12.7
Operating loss	(6.6)	(0.6)	(731.8)	(87.9)
Interest expense	(112.0)	(10.1)	(138.7)	(16.7)
Interest income	1.9	0.2	4.5	0.5
Other income, net	19.4	1.8	1.1	0.1
Reorganization items, net	(203.0)	(18.4)	—	—
Loss from continuing operations before income taxes	(300.3)	(27.2)	(864.9)	(103.9)
Income tax (benefit) expense	(49.9)	(4.5)	142.4	17.1
Loss from continuing operations	(250.4)	(22.7)	(1,007.3)	(121.0)
Income from discontinued operations, net of income taxes	0.7	0.1	24.0	2.9
Net loss	\$ (249.7)	(22.6)%	\$ (983.3)	(118.1)%
Basic loss per share:				
Loss from continuing operations	\$ (2.96)		\$ (11.95)	
Income from discontinued operations	0.01		0.28	
Net loss	\$ (2.95)		\$ (11.66)	
Diluted loss per share:				
Loss from continuing operations	\$ (2.96)		\$ (11.95)	
Income from discontinued operations	0.01		0.28	
Net loss	\$ (2.95)		\$ (11.66)	
Weighted-average number of shares outstanding:				
Basic	84.7		84.3	
Diluted	84.7		84.3	

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)

	Six Months Ended							
	June 25, 2021				June 26, 2020			
	Gross Profit	SG&A	R&D	Adjusted EBITDA	Gross Profit	SG&A	R&D	Adjusted EBITDA
Net loss	\$ 465.2	\$ 281.0	\$ 119.0	\$ (249.7)	\$ 63.6	\$ 462.4	\$ 160.3	\$ (983.3)
Adjustments:								
Interest expense, net	—	—	—	110.1	—	—	—	134.2
Income taxes	—	—	—	(49.9)	—	—	—	142.4
Depreciation ⁽¹⁾	34.9	(9.1)	(3.1)	47.1	35.9	(10.8)	(3.5)	50.2
Amortization	288.8	(1.7)	—	290.5	387.5	(1.7)	—	389.2
Restructuring charges, net	—	—	—	6.5	—	—	—	12.6
Non-restructuring impairment charges	—	—	—	64.5	—	—	—	63.5
Income from discontinued operations	—	—	—	(0.7)	—	—	—	(24.0)
Change in contingent consideration fair value	—	5.5	—	(5.5)	—	5.7	—	(5.7)
Significant legal and environmental charges	—	—	—	—	534.4	(39.7)	—	671.1
Losses (gains) on divestiture	—	—	—	0.8	—	—	—	(0.4)
Separation costs	—	(0.9)	—	0.9	—	(42.0)	—	42.0
Unrealized gain on equity investment	—	—	—	(11.7)	—	—	—	(3.0)
R&D upfront payment	—	—	—	—	—	—	(5.0)	5.0
Reorganization items, net	—	—	—	203.0	—	—	—	—
Share-based compensation	0.3	(4.7)	(1.0)	6.0	0.6	(10.6)	(2.1)	13.3
As adjusted:	<u>\$ 789.2</u>	<u>\$ 270.1</u>	<u>\$ 114.9</u>	<u>\$ 411.9</u>	<u>\$ 1,022.0</u>	<u>\$ 363.3</u>	<u>\$ 149.7</u>	<u>\$ 507.1</u>

⁽¹⁾ Includes \$1.3 million of accelerated depreciation in SG&A related to restructuring charges incurred during the six months ended June 25, 2021.

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT OPERATING INCOME ⁽¹⁾
(unaudited, in millions)

	Six Months Ended	
	June 25, 2021	June 26, 2020
Specialty Brands	\$ 398.7	\$ 473.2
Specialty Generics	58.6	112.4
Segment operating income	457.3	585.6
Unallocated amounts:		
Corporate and unallocated expenses ⁽²⁾	(48.3)	(110.2)
Depreciation and amortization	(337.7)	(439.4)
Share-based compensation	(6.0)	(13.3)
Restructuring charges, net	(6.5)	(12.6)
Non-restructuring impairment charges	(64.5)	(63.5)
Separation costs	(0.9)	(42.0)
R&D upfront payment	—	(5.0)
Opioid-related litigation settlement gain	—	8.3
Medicaid lawsuit	—	(639.7)
Operating loss	<u>\$ (6.6)</u>	<u>\$ (731.8)</u>

⁽¹⁾ During the three months ended September 25, 2020, the Company began excluding depreciation and share-based compensation from its evaluation of the operating results of its segments. As a result, prior period segment operating income has been recast to reflect this change on a comparable basis.

⁽²⁾ Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)

	Six Months Ended		Percent change	Currency impact	Constant-currency growth
	June 25, 2021	June 26, 2020			
Specialty Brands	\$ 789.9	\$ 1,013.4	(22.1)%	0.4 %	(22.5)%
Specialty Generics	314.5	353.3	(11.0)	0.2	(11.2)
Segment net sales	1,104.4	1,366.7	(19.2)	0.3	(19.5)
Medicaid lawsuit	—	(534.4)	*	*	*
Net sales	\$ 1,104.4	\$ 832.3	32.7 %	0.3 %	32.4 %

*Not meaningful

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)

	Six Months Ended		Percent change	Currency impact	Constant-currency growth
	June 25, 2021	June 26, 2020			
Specialty Brands					
Acthar	\$ 280.5	\$ 381.3	(26.4)%	— %	(26.4)%
Inomax	239.9	296.6	(19.1)	0.2	(19.3)
Ofirmev	19.3	127.3	(84.8)	—	(84.8)
Therakos	135.3	111.5	21.3	2.9	18.4
Amitiza	106.2	90.5	17.3	—	17.3
Other	8.7	6.2	40.3	—	40.3
Specialty Brands Total	789.9	1,013.4	(22.1)	0.4	(22.5)
Specialty Generics					
Hydrocodone (API) and hydrocodone-containing tablets	43.8	51.9	(15.6)	—	(15.6)
Oxycodone (API) and oxycodone-containing tablets	34.3	31.9	7.5	—	7.5
Acetaminophen (API)	97.2	99.6	(2.4)	—	(2.4)
Other controlled substances	127.1	161.4	(21.3)	0.3	(21.6)
Other	12.1	8.5	42.4	—	42.4
Specialty Generics Total	314.5	353.3	(11.0)	0.2	(11.2)
Segment net sales	1,104.4	1,366.7	(19.2)	0.3	(19.5)
Medicaid lawsuit	—	(534.4)	*	*	*
Net sales	\$ 1,104.4	\$ 832.3	32.7 %	0.3 %	32.4 %

*Not meaningful

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)

	June 25, 2021	December 25, 2020
Assets		
Current Assets:		
Cash and cash equivalents	\$ 1,254.9	\$ 1,070.6
Accounts receivable, net	449.8	538.8
Inventories	354.8	344.9
Prepaid expenses and other current assets	280.4	350.0
Total current assets	2,339.9	2,304.3
Property, plant and equipment, net	779.4	833.1
Intangible assets, net	5,829.4	6,184.5
Other assets	388.0	393.5
Total Assets	\$ 9,336.7	\$ 9,715.4
Liabilities and Shareholders' Equity		
Current Liabilities:		
Current maturities of long-term debt	\$ 1,703.0	\$ 3,587.9
Accounts payable	101.7	93.3
Accrued payroll and payroll-related costs	102.5	79.4
Accrued interest	27.7	26.9
Accrued and other current liabilities	372.5	331.2
Total current liabilities	2,307.4	4,118.7
Pension and postretirement benefits	33.4	34.6
Environmental liabilities	59.2	59.8
Deferred income taxes	67.3	80.6
Other income tax liabilities	98.6	100.1
Other liabilities	94.4	109.8
Liabilities subject to compromise	5,900.4	4,192.6
Total Liabilities	8,560.7	8,696.2
Shareholders' Equity:		
Preferred shares	—	—
Ordinary shares	18.9	18.8
Ordinary shares held in treasury at cost	(1,616.1)	(1,616.1)
Additional paid-in capital	5,593.6	5,587.6
Retained deficit	(3,211.2)	(2,961.5)
Accumulated other comprehensive loss	(9.2)	(9.6)
Total Shareholders' Equity	776.0	1,019.2
Total Liabilities and Shareholders' Equity	\$ 9,336.7	\$ 9,715.4

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)

	Six Months Ended	
	June 25, 2021	June 26, 2020
Cash Flows From Operating Activities:		
Net loss	\$ (249.7)	\$ (983.3)
Adjustments to reconcile net cash from operating activities:		
Depreciation and amortization	337.6	439.4
Share-based compensation	6.0	13.3
Deferred income taxes	(13.2)	314.1
Non-cash impairment charges	64.5	63.5
Reorganization items, net	15.7	—
Other non-cash items	(15.5)	(12.9)
Changes in assets and liabilities:		
Accounts receivable, net	89.0	83.6
Inventories	(14.3)	(27.2)
Accounts payable	(2.3)	(45.7)
Income taxes	22.8	(219.8)
Medicaid lawsuit	(3.2)	639.7
Other	86.6	(40.1)
Net cash from operating activities	<u>324.0</u>	<u>224.6</u>
Cash Flows From Investing Activities:		
Capital expenditures	(29.2)	(31.3)
Proceeds from divestitures, net of cash	15.7	(3.5)
Other	0.3	6.0
Net cash from investing activities	<u>(13.2)</u>	<u>(28.8)</u>
Cash Flows From Financing Activities:		
Repayment of external debt	(123.5)	(129.6)
Debt financing costs	—	(9.1)
Repurchase of shares	—	(0.3)
Other	—	(19.2)
Net cash from financing activities	<u>(123.5)</u>	<u>(158.2)</u>
Effect of currency rate changes on cash	0.3	(0.5)
Net change in cash, cash equivalents and restricted cash	<u>187.6</u>	<u>37.1</u>
Cash, cash equivalents and restricted cash at beginning of period	<u>1,127.0</u>	<u>822.6</u>
Cash, cash equivalents and restricted cash at end of period	<u>\$ 1,314.6</u>	<u>\$ 859.7</u>
Cash and cash equivalents at end of period	\$ 1,254.9	\$ 818.3
Restricted cash included in prepaid expenses and other assets at end of period	23.4	5.4
Restricted cash included in other long-term assets at end of period	36.3	36.0
Cash, cash equivalents and restricted cash at end of period	<u>\$ 1,314.6</u>	<u>\$ 859.7</u>